Commonwealth Business Bank (Ca) (CWBB) 11.3500

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Commonwealth Business Bank (Ca) (CWBB) 11.3500 $CWBB

Commonwealth Business Bank declares full year earnings of USD11.2m
M2 - Mon Feb 09, 5:03AM CST
Commonwealth Business Bank (OTCQB:CWBB), a full-service commercial bank, reported on Saturday that its full year net income available to common shareholders amounted to a record USD11.2m, or USD2.72 per diluted common share for 2014.

Commonwealth Business Bank Reports Record Earnings of $11.2 million or $2.72 per Diluted Common Share for 2014
Business Wire - Fri Feb 06, 8:21PM CST
--Net income of $11.2 million or $2.72 per diluted common share;

Commonwealth Bank: Twice The Growth, Half The Cost - 60% Upside In 6 Months, Target Price $37
The Capitalist - Seeking Alpha - Thu Nov 13, 8:28AM CST
Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks. This article provides a summary of five of the key players in the "Asian American Bank space": Commonwealth Bank ( OTCQB:CWBB ),...
EWBC: 41.30 (+0.27), HAFC: 20.95 (-0.05), CATY: 28.50 (-0.09), BBCN: 14.59 (+0.10)

Commonwealth Business Bank Reports Increased Net Income, Steady Loan Growth and Improved Net Interest Margin for Third Quarter 2014
Business Wire - Thu Oct 30, 4:00AM CDT
--Net income increased 20.9% to $2.9 million, or $0.71 per diluted common share.

Commonwealth Business Bank Reports Second Quarter 2014 Net Income of $2.4 Million, or $0.59 per Diluted EPS, and Improved Asset Quality
Business Wire - Wed Jul 30, 6:08PM CDT
Commonwealth Business Bank ("CBB" (OTCQB: CWBB) today announced that for the second quarter of 2014, net income available to common shareholders was $2.4 million, or $0.59 per diluted common share from $3.4 million, or $0.84 per diluted common share, for the first quarter of 2014, and from $2.2 million, or $0.58 per diluted common share, for the same quarter of 2013.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

TSA PreCheck Study Reveals Time Savings and Travel Insights

Updated Category News Views 379

Understanding TSA PreCheck's Impact on Travelers The latest survey reveals some interesting insights about TSA PreCheck, especially concerning the time savings that members experience at security checkpoints. Conducted by Upgraded Points, this enlightening study assessed the experience of over 1,500 travelers to evaluate the true advantages of holding a TSA PreCheck...

Continue Reading
Intermap Technologies Enhances Geospatial Solutions with New Offering

Updated Category News Views 217

Intermap Technologies Announces New Prospectus Supplement DENVER – Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF), a recognized leader in 3D geospatial products and intelligence solutions, has filed a prospectus supplement in the context of a strategically planned public offering. This initiative signifies a promising step forward, with the company aiming to...

Continue Reading
Urgent Investor Notice: Humacyte Legal Claims Investigation

Updated Category News Views 94

Critical Deadline for Humacyte Investors Approaches As time runs short, investors in Humacyte, Inc. (NASDAQ: HUMA) should pay attention. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims on behalf of investors who have suffered losses exceeding $75,000 due to potential violations in federal securities laws. Understanding Your...

Continue Reading
Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab

Updated Category News Views 226

Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab Natalie Bartholomew, a highly recognized advocate for women in financial services, will be the featured speaker for the Women in Banking session at Alkami Co:lab 2026. Her expertise and passion are expected to inspire attendees and foster discussions around women's roles in the financial sector. Alkami...

Continue Reading
Investors Anticipate Strong Earnings from OPAL Fuels Soon

Updated Category News Views 161

OPAL Fuels Earnings Report Insights OPAL Fuels OPAL is preparing to release its quarterly earnings report soon, and investors are keenly interested in the results. As the anticipated date for this report approaches, it is essential for investors to stay informed and understand what the expectations are. Projected Earnings Overview Analysts project that OPAL Fuels will...

Continue Reading